Showing 3891-3900 of 5773 results for "".
- Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitishttps://modernod.com/news/tarsus-completes-enrollment-for-the-pivotal-phase-3-saturn-2-trial-of-tp-03-to-treat-demodex-blepharitis/2480610/Tarsus Pharmaceuticals announced it has completed enrollment of Saturn-2, the company’s second pivotal phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for patients with Demodex blepharitis and executed a $175 million credit facility with Hercules Capital and Silicon
- GlobalData: Glaucoma Market to Grow to $3.5 Billion by 2030, Driven by Launch of New Pipeline Productshttps://modernod.com/news/globaldata-glaucoma-market-to-grow-to-35-billion-by-2030-driven-by-launch-of-new-pipeline-products/2480609/Steady growth is expected for the glaucoma market across the seven major markets* from $2.8 billion in 2020 to $3.5 billion in 2030, at a compound annual growth rate (CAGR) of 2.0%, according to GlobalData. According to the leading data and analytics company’s latest re
- Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 Granted Orphan Drug Designation by EMAhttps://modernod.com/news/neurophth-therapeutics-treatment-of-lebers-hereditary-optic-neuropathy-gene-therapy-nr082-granted-orphan-drug-designation-by-ema/2480605/Neurophth Therapeutics announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD) for the company's leading gene therapy drug candidate, NR082 (rAAV2-ND4), for the treatment of Leber's hereditary opt
- Nanodropper and Lumata Health Launch Partnership Aimed at Improving Patient Carehttps://modernod.com/news/nanodropper-and-lumata-health-launch-partnership-aimed-at-improving-patient-care/2480600/Nanodropper recently announced a partnership with Lumata Health, which includes the launch of a pilot program bringing the Nanodropper Adaptor device to Lumata Health network patients across the United States. Lumata Health is a tech-enabled health care service company fo
- MeiraGTx Receives Clinical Development Milestone Payment from Janssenhttps://modernod.com/news/meiragtx-receives-clinical-development-milestone-payment-from-janssen/2480599/MeiraGTx Holdings announced that it has received a $30 million payment from Johnson & Johnson's Janssen Pharmaceuticals for a clinical milestone in the phase 3 Lumeos trial of botaretigene sparoparvovec (AAV-RPGR), an investigational gene therapy for the treatment of X-linked retinit
- Mitotech to Host Key Opinion Leader Webinar on Visomitin: A Potential Treatment for Dry Eye Diseasehttps://modernod.com/news/mitotech-to-host-key-opinion-leader-webinar-on-visomitin-a-potential-treatment-for-dry-eye-disease/2480596/Mitotech announced that it will host a key opinion leader (KOL) webinar on Visomitin and its potential for the treatment of dry eye disease, on Friday, February 4, 2022 at 8 am EST (14.00 CET). The event will feature presentations from John D. Sheppard, MD, MMSc (Virginia Eye Consu
- Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseaseshttps://modernod.com/news/kriya-licenses-next-generation-complement-targeted-gene-therapies-for-the-treatment-of-geographic-atrophy-and-other-ocular-diseases/2480593/Kriya Therapeutics announced an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases. "This partne
- Yehia Hashad, MD, to Join Bausch + Lomb as Executive Vice President of Research & Development and CMOhttps://modernod.com/news/yehia-hashad-md-will-join-bausch-lomb-as-executive-vice-president-of-research-development-and-cmo/2480581/Bausch Health Companies has announced that Yehia Hashad, MD, will join Bausch + Lomb as executive vice president of Research & Development and Chief Medical Officer (CMO), effective January 31, 2022. Dr. Hashad will join Bausch + Lomb from Allergan/AbbVie, where for the past 11
- Foundation Fighting Blindness Promotes Jason Menzo to President and Chief Operating Officerhttps://modernod.com/news/foundation-fighting-blindness-promotes-jason-menzo-to-president-and-chief-operating-officer/2480580/The Foundation Fighting Blindness announced the promotion of Jason Menzo to president and chief operating officer, effective immediately. Since joining the Foundation in 2018, Mr. Menzo has had a profound positive impact on redefining the non-profit’s operations, includi
- Euclid Systems Launches MyEuclid Customer Portalhttps://modernod.com/news/euclid-systems-launches-myeuclid-customer-portal/2480579/Euclid Systems announced an initial launch of MyEuclid, a new interactive, web-based customer portal designed to help drive practice efficiency and optimize Euclid Ortho-K fits. Used on millions of eyes a